NCT07161453

Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology

A Multicenter, Prospective, Real-world Study Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 500 (estimated)
• Sponsor: Liaoning Cancer Hospital & Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is to evaluate the efficacy and safety of different postoperative adjuvant regimens in patients with resectable adenocarcinoma of the esophagogastric junction who underwent radical surgery after neoadjuvant chemotherapy combined with immunotherapy and achieved pCR in postoperative pathology

Conditions

• Gastric / Gastroesophageal Junction Adenocarcinoma

Interventions

Type	Name	Description
DRUG	SOX plus PD-1 inhibitor	SOX or XELOX plus PD-1 inhibitor
DRUG	PD-1 / PD-L1 monoclonal antibody	PD-1/PD-L1 monoclonal antibody
DRUG	SOX Chemotherapy	SOX or XELOX
DRUG	Tegafur-Ugotex or Capecitabine	Tegafur-Ugotex or Capecitabine

Timeline

• Start date: 2025-09-30
• Primary completion: 2027-09-30
• Completion: 2027-12-31
• First posted: 2025-09-08
• Last updated: 2025-09-08